431888-57-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Chloro-4-(Methoxycarbonyl)benzoic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 2-Chloro-4-(Methoxycarbonyl)benzoic acid is utilized as a precursor in the production of pesticides and other agrochemicals, enhancing their effectiveness in agricultural applications.
Used in Organic Synthesis:
2-Chloro-4-(Methoxycarbonyl)benzoic acid serves as a versatile building block in organic synthesis, allowing for the creation of a wide range of organic molecules with diverse applications.
Used in Medicinal Chemistry:
2-Chloro-4-(Methoxycarbonyl)benzoic acid is employed in medicinal chemistry for the design and synthesis of novel compounds with potential therapeutic applications, contributing to the advancement of medical treatments.

Upstream product

• 18643-84-0 2-chloro-1,4-benzenedicarboxylic acid dimethyl ester 

Downstream Products

• 55737-63-8 3-Chloro-4-chlorocarbonyl-benzoic acid methyl ester 
• 431888-58-3 1-tert-butyl 4-methyl 2-chloroterephthalate 
• 879087-10-2 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonylmethyl)benzamide 
• 1190947-57-9 2-chloro-4-(methylsulfonylmethyl)benzoic acid 
• 1190947-56-8 tert-butyl 2-chloro-4-(methylsulfonylmethyl)benzoate 
• 879088-82-1 tert-butyl 4-(bromomethyl)-2-chlorobenzoate 
• 1190947-53-5 tert-butyl 2-chloro-4-(hydroxymethyl)benzoate 

Relevant academic research and scientific papers

BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as "BHBA compou

Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway

Potent and efficacious inhibitors of the hedgehog pathway for the treatment of cancer have been prepared using the 2-pyridyl biphenyl amide scaffold common to the clinical lead GDC-0449. Analogs with polar groups in the para-position of the aryl amide ring optimized potency, had minimal CYP inhibition, and possessed good exposure in rats. Compounds 9d and 14f potently inhibited hedgehog signaling as measured by Gli1 mRNA and were found to be equivalent or more potent than GDC-0449, respectively, when studied in a Ptch+/- medulloblastoma allograft model, that is, highly dependent on hedgehog signaling.

PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

The invention provides novel inhibitors of hedgehog signaling that are useful as s therapeutic agent for treating malignancies where the compounds have the general formula (I): where A, X, Y R1, R2, R3, R4, m and n are as described herein.

Pyridyl inhibitors of hedgehog signalling

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.

Process and intermediates for the preparation of halogenated protease inhibitors

This invention relates to novel intermediate compounds which are useful for producing the halogenated protease inhibitors that are the subject matter of U.S. Pat. No. 4,469,885. In particular, the invention relates to novel methods and intermediates for making said protease inhibitors, the intermediate compounds being of the formula: STR1 wherein R1 is: (a) straight or branched chain lower alkyl having 1-6 carbon atoms; or (b) H; wherein R6 is: (a) straight or branched chain higher alkyl having 13-25 carbon atoms; or (b) straight or branched chain higher alkenyl having 13-25 carbon atoms; wherein R5 is: (a) straight or branched chain lower alkyl having 1-6 carbon atoms; or (b) benzyl; wherein R7 is: (a) straight or branched chain lower alkyl having 1-6 carbon atoms; or (b) H; wherein R2 is: (a) --Cl, --Br, or --I; or (b) --CF3.